Feihe
Product brand
UnclaimedChinese dairy company
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile yet.
History
Feihe's origins date to 1962 in Qiqihar, Heilongjiang, a region with an important dairy-production base. The company initially developed as a regional dairy producer and gradually expanded its processing activities and consumer distribution. Its later identity was shaped by the growth of China's packaged-milk and infant-formula markets, where manufacturing scale, quality assurance, and retail reach became increasingly important. During the expansion of China's infant-formula industry, Feihe developed products for infants, toddlers, older children, and adults. The company increasingly concentrated its brand resources on infant nutrition, where consumer trust and product specialization allowed domestic companies to compete with established international suppliers. The Firmus name became closely associated with Feihe's infant-formula business, while the broader Feihe identity served as the corporate and national consumer brand. A central part of Feihe's strategy has been vertical integration. The company has invested in dairy farms, feed and raw-milk sourcing, processing plants, packaging, logistics, and quality-control systems. It has presented this structure as a way to improve traceability and control over the production chain. The company has also promoted research and development focused on infant and child nutrition, including products designed for Chinese consumers. Feihe expanded its presence through supermarkets, specialty maternal-and-child retailers, pharmacies and other offline channels, as well as e-commerce. Advertising and educational marketing helped it move from a regional dairy name toward a nationally recognized infant-formula brand. The company has used premium product tiers, stage-based formulas, and specialized nutrition offerings to address different family budgets and feeding requirements. In 2019, China Feihe Limited listed on the Hong Kong Stock Exchange under stock code 6186. The listing marked an important corporate milestone and provided access to public capital markets. After the listing, the company continued investing in capacity, product development, brand building, and distribution. Its public reporting has also highlighted the importance of retail execution, research capabilities, raw-milk security, and consumer confidence. Feihe operates in a demanding environment. China's infant-formula market has experienced regulatory tightening, more sophisticated consumers, intense competition, and demographic pressure caused by falling births. These conditions have encouraged the company to defend its core infant-formula position while developing products for older children and adults and seeking additional growth through innovation and premiumization. The brand remains active as the principal consumer identity associated with China Feihe Limited.
Products and positioning
A leading Chinese infant-formula and dairy-nutrition brand emphasizing domestic research, local consumer needs, controlled supply chains, and premium family nutrition.
Infant formula
Firmus infant formula
Firmus is one of the best-known infant-formula identities associated with Feihe. The range has included formulas for different stages of infancy and early childhood, with product segmentation intended to address age-specific nutritional requirements. It is marketed primarily through China's maternal-and-child retail network, general retail, and e-commerce channels.
Infant and toddler nutrition
Feihe infant and toddler formula
Feihe-branded infant and toddler formulas form the company's core consumer offering. The products are organized around developmental stages and are supported by the company's domestic dairy-processing and quality-control infrastructure. The portfolio is intended for families seeking Chinese-produced formula and includes mainstream, premium, and specialized positioning.
Children's dairy nutrition
Children's nutrition products
Feihe has extended beyond infant formula into products for preschool and school-age children. These products broaden the brand relationship beyond the first years of life and may include children's milk powder and other nutrition-focused dairy products. Exact product availability varies by market and product generation.
Adult nutrition
Adult nutrition products
The company also participates in adult milk powder and nutrition categories. These products diversify Feihe's dairy portfolio and allow the group to serve households across multiple life stages, although infant nutrition remains the brand's most prominent commercial association.
Controversies
2020
China Feihe responds to Blue Orca report
China Feihe issued a clarification after Blue Orca Capital published a report containing allegations about the company's financial performance. Feihe said the allegations were unfounded or misrepresented facts and advised shareholders to treat them cautiously.
2019
GMT Research questions China Feihe's business sustainability
GMT Research published a short-seller report questioning China Feihe's growth and the sustainability of its business. The article says the report did not present conclusive data or materials establishing fraud, and notes that GMT described the report as not a conventional short-selling report.
Brand decisions
2019
Public-market listing to support expansionStrategyBackground
China Feihe operated in a competitive infant-formula market requiring continued investment in manufacturing, research, compliance, and distribution.
Action taken
The parent company completed a listing on the Hong Kong Stock Exchange.
Aftermath
The listing increased the company's access to public capital markets and formalized its status as a publicly traded dairy and infant-nutrition group.
- Greater emphasis on vertical integration and premium nutritionStrategy
Background
Infant-formula consumers place strong emphasis on safety, traceability, quality consistency, and specialized nutritional claims.
Action taken
Feihe invested in controlled dairy sourcing, production infrastructure, research, premium product tiers, and stage-based formula development.
Aftermath
The approach strengthened the brand's domestic supply-chain positioning while increasing its exposure to regulatory, demographic, and competitive pressures.
Recent events
- Unconfirmed
Reported
Nvidia-backed Firmus withdraws planned IPO citing market volatility[6]
Firmus, an Australian AI data center operator backed by Nvidia, withdrew its planned mega initial public offering, citing market volatility and conditions. The company said its board determined that the terms of the proposed offering did not adequately reflect the strength of its business and long-term growth outlook and concluded that proceeding with the offer was not in the best interests of the company and its shareholders.
Reported
China Feihe announces conditional offer for Yuan Sheng Tai Dairy Farm[7]
China Feihe announced that it proposed to make a conditional voluntary takeover offer for Yuan Sheng Tai Dairy Farm and to pay cash to cancel all outstanding share options. If successful, China Feihe would become the controlling shareholder while Yuan Sheng Tai would remain listed.
Reported
China Feihe responds to Blue Orca report[4]
China Feihe issued a clarification after Blue Orca Capital published a report containing allegations about the company's financial performance. Feihe said the allegations were unfounded or misrepresented facts and advised shareholders to treat them cautiously.
- Unconfirmed
Reported
Feihe wins the TPM Award[8]
Feihe received the Global Excellence in Manufacturing Award TPM Award from the JIPM review committee.
Reported
China Feihe wins the TPM Global Excellence in Manufacturing Award[9]
China Feihe received the TPM Global Excellence in Manufacturing Award from the Japan Institute of Plant Maintenance (JIPM) review committee, according to the article.
Reported
GMT Research questions China Feihe's business sustainability[5]
GMT Research published a short-seller report questioning China Feihe's growth and the sustainability of its business. The article says the report did not present conclusive data or materials establishing fraud, and notes that GMT described the report as not a conventional short-selling report.
Sources11 sources
- 1China Feihe official websitefeihe.com
- 2Hong Kong Stock Exchange equity market datahkex.com.hk
- 3China Feihe Limited company filingswww1.hkexnews.hk
- 4China Feihe responds to Blue Orca reportfinance.sina.com.cn
- 5GMT Research questions China Feihe's business sustainabilityfinance.sina.com.cn
- 6英伟达投资的Firmus以市场波动为由撤回IPO计划bbc.co.uk
- 7中国飞鹤拟要约收购原生态牧业finance.sina.com.cn
- 8飞鹤荣获TPM奖food.china.com.cn
- 9中国飞鹤获全球卓越制造大奖TPM奖finance.sina.com.cn
- 10Nvidia-backed Aussie AI firm Firmus withdraws historic IPO, citing market volatilitycnbc.com
- 11Stock futures rise as tech shares rebound following sell-off: Live updatescnbc.com
Cite this profile: Cite the canonical profile. /brand-wiki/feihe · Editorial policy · How profiles are compiled